Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021

Delivered FY2020 Management Guidance with Results Driven by +16% Underlying Revenue Growth of 14 Global Brands (e.g., ENTYVIO ® +26.2% YOY, TAKHZYRO® +30.0% YOY, Immunoglobulin + 15.7% YOY) Accelerated Cost Synergies and Achieved $2.3 Billion Targe...

Full "IntellAsia: Resources" article